Poor
Not Aligned
Patient Risk:
Moderate
Summary
Most pharmacology/indication and several adverse-effect claims align with the provided label excerpts, but multiple claims are explicitly absent from the label (notably pill imprint identity/strength and manufacturer, plus generic/patent regulatory assertions). These unsupported specifics substantially reduce alignment.
Category Scores
Accurate Statements
Quetiapine fumarate is an atypical antipsychotic medication.
11 DESCRIPTION
Quetiapine fumarate is prescribed to treat schizophrenia.
1.1 Schizophrenia
Quetiapine fumarate is prescribed to treat bipolar I disorder for manic or mixed episodes.
1.2 Bipolar Disorder (acute treatment of manic or mixed episodes associated with bipolar I disorder)
Quetiapine fumarate is prescribed for bipolar disorder depressive episodes.
1.2 Bipolar Disorder (acute treatment of depressive episodes associated with bipolar disorder)
Quetiapine fumarate is prescribed for major depressive disorder as adjunctive therapy to antidepressants for inadequate response to antidepressant treatment.
1.3 Adjunctive Treatment of Major Depressive Disorder (MDD)
Common side effects can include somnolence (drowsiness).
6.1 Clinical Studies Experience (somnolence)
Common side effects can include dizziness, dry mouth, constipation, weight gain, and blurred vision.
6.1 Clinical Studies Experience (dizziness, dry mouth, constipation, vision blurred, weight gain); plus 5 WARNINGS AND PRECAUTIONS (metabolic/weight gain)
More serious side effects can include cerebrovascular adverse reactions including stroke in elderly patients with dementia-related psychosis.
5.3 Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis
More serious side effects can include suicidal thoughts and behaviors.
5.2 Suicidal Thoughts and Behaviors in Adolescents and Young Adults
More serious side effects can include hyperglycemia/high blood sugar and dyslipidemia/high cholesterol.
5.5 Metabolic Changes (hyperglycemia/diabetes mellitus; dyslipidemia)
More serious side effects can include leukopenia/neutropenia (low white blood cell counts).
5.10 Leukopenia, Neutropenia, and Agranulocytosis
Unsupported Statements
The pill with imprint "E56" contains 100 mg of quetiapine fumarate.
Imprint/strength identity is not provided anywhere in the supplied prescribing information excerpts.
The manufacturer of the E56 pill imprint containing 100 mg of quetiapine fumarate is Teva Pharmaceuticals.
The supplied prescribing information excerpts do not identify pill imprints or manufacturers by imprint.
The original patents for quetiapine (Seroquel) have long expired, allowing widespread availability of generic versions.
Patent expiration/market-availability statements are not present in the supplied label excerpts.
Generic drugs must meet the same strict standards for safety, efficacy, and quality as brand-name counterparts.
General regulatory statements about generic standards are not present in the supplied label excerpts.
Regulatory bodies such as the FDA approve generic medications after rigorous review.
General statements about FDA review of generics are not present in the supplied label excerpts.
Contradictions
Low
AI Statement
None of the provided claims directly conflict with the supplied labeling excerpts.
Label Reference
Important Omissions
Key boxed warning and major safety monitoring details beyond the specifically mentioned items (e.g., full scope of boxed warnings such as mortality in elderly patients with dementia-related psychosis and additional related monitoring language).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported imprint-specific claims (identity/strength/manufacturer) could plausibly lead to dosing or product-selection errors. Other supported safety statements were generally consistent with label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple claims are not supported by the FDA prescribing information provided, including imprint-specific strength/manufacturer and generic/patent/regulatory assertions.
Suggested Improvement
Remove or replace imprint/manufacturer/patent/generic-regulatory claims with statements that are explicitly supported by the prescribing information excerpts (e.g., indication and label-described safety/monitoring content).